(Q51561907)

7 April 2018

title

Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR). (English)

1 reference

7 April 2018

author name string

Stewart PM

1

1 reference

7 April 2018

Stewart SE

2

1 reference

7 April 2018

Clark PM

3

1 reference

7 April 2018

Sheppard MC

4

1 reference

7 April 2018

publication date

1 March 1999

1 reference

7 April 2018

published in

Clinical Endocrinology

1 reference

7 April 2018

volume

50

1 reference

7 April 2018

issue

3

1 reference

7 April 2018

page(s)

295-299

1 reference

7 April 2018

Epidemiology of acromegaly in the Newcastle region.

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00660.X

Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00660.X

Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00660.X

Long-term follow-up of patients with hyperprolactinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00660.X

The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00660.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00660.X

Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00660.X

Premature mortality due to cardiovascular disease in hypopituitarism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00660.X

Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00660.X

Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00660.X

Acromegaly: treatment after 100 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00660.X

Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00660.X

Hyperprolactinemia. Long-term effects of bromocriptine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00660.X

Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.1999.00660.X

10.1046/J.1365-2265.1999.00660.X

21 January 2018

Identifiers

DOI

1 reference

7 April 2018

1 reference

7 April 2018